Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Long-Term Investments (2016 - 2019)

Lineage Cell Therapeutics (LCTX) has 4 years of Long-Term Investments data on record, last reported at $19.0 million in Q4 2019.

  • For Q4 2019, Long-Term Investments fell 6.17% year-over-year to $19.0 million; the TTM value through Dec 2019 reached $19.0 million, down 6.17%, while the annual FY2019 figure was $19.0 million, 6.17% down from the prior year.
  • Long-Term Investments reached $19.0 million in Q4 2019 per LCTX's latest filing, up from $17.7 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $110.8 million in Q3 2017 and bottomed at $4.4 million in Q1 2016.
  • Average Long-Term Investments over 4 years is $51.7 million, with a median of $44.8 million recorded in 2016.
  • Peak YoY movement for Long-Term Investments: skyrocketed 1566.86% in 2017, then tumbled 74.48% in 2018.
  • A 4-year view of Long-Term Investments shows it stood at $100.0 million in 2016, then plummeted by 31.76% to $68.2 million in 2017, then tumbled by 70.32% to $20.2 million in 2018, then decreased by 6.17% to $19.0 million in 2019.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $19.0 million in Q4 2019, $17.7 million in Q3 2019, and $36.5 million in Q2 2019.